ARCUS BIOSCIENCES INC (RCUS)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RCUS
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RCUS | Director | 63 | [] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| GILD | Chief Medical Officer | 62 | ["board-certified internist, hematologist and oncologist", "more than 25 years of experience in developing and delivering innovative medicines", "Senior Vice President and Global Head of Development at Sanofi", "Executive Vice President and Global Head of Research & Development at Atara Biotherapeutics", "development and medical affairs roles at Genentech, Bayer Healthcare Pharmaceuticals and Amgen", "Professor of Medicine at the University of Freiburg Hospital in Freiburg, Germany", "completed medical training in Freiburg, Germany; Basel, Switzerland; and Chicago"] | [] | 2025 |
Biography sourced from the proxy statement filing.
Dietmar Berger, M.D., Ph.D. has served as a member of our Board since February 2025. Dr. Berger joined Gilead Sciences, Inc. (Nasdaq: GILD) in January of 2025 as its Chief Medical Officer. In his role at Gilead, he is responsible for leading the company s clinical development and medical affairs strategy for all of Gilead s medicines throughout the product lifecycle. With over 25 years of experience in preclinical and clinical drug development, Dr. Berger plays a pivotal role in advancing Gilead s mission to deliver transformative therapies to patients worldwide. Prior to Gilead, Dr. Berger served in executive leadership positions at Sanofi, Genentech, Bayer HealthCare and Amgen. Dr. Berger is a board-certified Internist, Hematologist and Oncologist with full academic credentials and clinical experience. Dr. Berger was selected to be appointed to the Board pursuant to the Investor Rights Agreement and we believe he is able to make valuable contributions to the Board due to his extensive clinical development experience.